Clinical considerations of hyaluronidase as an adjunct to subcutaneous rituximab injection

Abstract

Subcutaneous rituximab injectables are formulated with recombinant human hyaluronidase as an adjunct to facilitate the absorption of the large volume of rituximab. We review the clinical considerations regarding the potential for systemic hyaluronidase toxicity and increased systemic absorption of subcutaneous or topical drugs administered subsequent to rituximab.

Keywords

Hyaluronidase rituximab subcutaneous injection dermis antineoplastic agent

Get full access to this article

View all access options for this article.

References

Genentech. Rituximab SC presentation to the Oncology Drug Advisory Committee. Bethesda, MD; 29 March 2017.

Halozyme Therapeutics, Inc. Hylenex product monograph. San Diego, CA; February 2016.

Frost

. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007; 4: 427–440.

Liptrott

Cambon

Berthillon

et al.

Minimization of administration route errors with subcutaneous rituximab. J Oncol Pharm Pract 2016; 22: 186–187.

Hoffman-La Roche Ltd. RITUXAN® SC product monograph. Mississauga, Ontario; 21 March 2018.

Assouline

Buccheri

Delmer

et al.

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol 2015; 80: 1001–1009.

Aspen Pharmacare Canada Inc. EMLA product monograph. Toronto, Ontario; 8 August 2016.

Aspen Pharmacare Canada Inc. EMLA cream product monograph. Dublin, Ireland; 27 May 2017.